



## Company Fact Sheet

### Headquarters:

Nuvaira, Inc.  
3750 Annapolis Lane North  
Suite 105  
Minneapolis, MN 55447  
763.450.2800  
[www.nuvaira.com](http://www.nuvaira.com)

### Number of Employees:

30+

### Products and Intended use:

The Nuvaira™ Lung Denervation System is a novel, catheter-based system designed to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves in a procedure called Targeted Lung Denervation\* (TLD). The Nuvaira System is comprised of a console and single use treatment package that contains the dNerva™ Dual Cooled RF Catheter.

### AIRFLOW-2 RCT:

The Nuvaira System and procedure were used in the recently completed multi-center, sham controlled randomized clinical trial, which took place in Austria, France, Germany, the Netherlands and the United Kingdom. The patient population included people suffering from moderate to severe COPD.

### RELIEF-1 Trial:

The Nuvaira System and procedure are being used in the first multi-center TLD clinical trial for severe asthma taking place in France, Germany, the Netherlands and the United Kingdom.

### Media Resource:

Dennis Wahr, M.D., President and CEO

### Media Inquiries:

Amy Wolter  
+1 (763) 450-5676  
[info@nuvaira.com](mailto:info@nuvaira.com)

###

\*Targeted Lung Denervation is currently under clinical investigation for chronic obstructive pulmonary disease and asthma and is not yet commercially available.

Nuvaira and dNerva are trademarks of Nuvaira, Inc.